Total
0
Shares
Acerus (TSX:ASP) expands NATESTO distribution worldwide
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Acerus (ASP) expands NATESTO® distribution worldwide
  • Maylen Farma to market treatment in 20 countries across Europe, Central Asia and the Middle East
  • Maylen is a privately-owned pharmaceutical company based in Lugano, Switzerland
  • Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products
  • Acerus Pharmaceuticals Corporation (ASP) is up 20.00 per cent and is trading at C$0.060 at 1:23 pm ET

Acerus Pharmaceuticals has granted Maylen Farma rights to market NATESTO® in 20 countries across Europe, Central Asia, and the Middle East.

Maylen is a privately-owned pharmaceutical company based in Lugano, Switzerland, specializing in bringing innovative pharmaceutical products and healthcare services to patients in emerging markets.

Nations covered by the agreement with Acerus include Belarus, Georgia, Ukraine, Azerbaijan, Uzbekistan, Tajikistan, and many more.

“We are delighted to be partnering with Maylen in the commercialization of NATESTO® across these 20 rapidly expanding markets,” said Ed Gudaitis, President and Chief Executive Officer of Acerus.

“Maylen’s extensive reach and expertise will provide – assuming regulatory approval across all covered countries – access to a combined population of approximately 220 million," added Gudaitis.

"We are excited by the opportunity this will provide to bolster our top-line growth trajectory,” concluded Gudaitis.

On March 11, Acerus released its Q4 and full year, 2020 report. Acerus saw an increase in its Q4 which reflects the closing of the previously-announced rights offering in November 2020 that raised C$13.2 million.

Acerus also entered into an agreement with Torreya Partners LLC to identify strategic options for product acquisition and growth capital.

Natesto® is also expected to be available in Canada sometime in mid-2021. The manufacturing of its product is on-going and should return to the Canadian market.

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, focusing on the field of men’s health.

Acerus Pharmaceuticals Corporation (ASP) is up 20.00 per cent and is trading at C$0.060 at 1:23 pm ET.

More From The Market Herald
Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

" Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Neovasc (NVCN) has received approval from the FDA for the Investigational Device Exemption regarding its COSIRA-II IDE Clinical Trial.
Relay Medical (CSE:RELA) & Fio to provide rapid COVID-19 testing at TIFF

" ScreenPro (CSE:SCRN) providing COVID-19 testing at TIFF

ScreenPro (SCRN) is providing COVID-19 testing services at this year’s Toronto International Film Festival.
Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

" Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.
VitalHub (TSXV:VHI) signs multi-year contract with Hampshire Hospitals NHS Foundation Trust

" Skylight Health Group (TSXV:SLHG) acquires Pennsylvania Clinic Group

Skylight Health Group Inc. (SLHG) executes the definitive agreements to acquire a controlling interest in Aspire Health Concepts, Inc.